Live Breaking News & Updates on ஃப்ரான்ஸ் வெர்னர் ஹாஸ்|Page 4
Stay updated with breaking news from ஃப்ரான்ஸ் வெர்னர் ஹாஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deia Tras la fallida eficacia del fármaco, demandan su correcta inmunización iker mojón / bilbao 02.07.2021 | 01:19 Una voluntaria de CureVac, en el momento de recibir la vacuna en Cruces. Efe ensayo de la empresa farmacéutica los voluntarios del ensayo se encuentran a la espera de conocer qué pasos deben seguir en su proceso de vacunación o si tienen que ser o no vacunados. Algunos de estos lamentan no saber cómo proceder con su vacunación. Desde el Departamento de Salud aseguran que desde el pasado 18 de junio comenzaron a ponerse en contacto por correo electrónico ....
UEFA stoppt Ticketverkauf für Fans aus Grossbritannien telebasel.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telebasel.ch Daily Mail and Mail on Sunday newspapers.
Covid Vaccine From Germany s CureVac Just 48% Effective By Michelle FITZPATRICK 06/30/21 AT 7:58 PM Germany s CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna. The outcome had been expected after poor interim data were released earlier this month. The company in part blamed the unprecedented context of 15 strains circulating among the trial volunteers, as well as varying responses across age groups. The Covid vaccines developed by Germany s BioNTech in partnership with US giant Pfizer and by US firm Moderna based on the same novel messenger RNA technology were approved earlier on in the pandemic after showing around 95 percent efficacy. ....
den Impfstoffkandidaten der ersten Generation, zeigen Schutzwirkung in Altersgruppe von 18 bis 60 Jahren DGAP-News: CureVac / Schlagwort(e): Studienergebnisse CureVacs Daten der finalen Analyse der Phase 2b/3-Studie für CVnCoV, den Impfstoffkandidaten der ersten Generation, zeigen Schutzwirkung in Altersgruppe von 18 bis 60 Jahren 30.06.2021 / 22:30 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
CureVacs Daten der finalen Analyse der Phase 2b/3-Studie für CVnCoV, den Impfstoffkandidaten der ersten Generation, zeigen Schutzwirkung in Altersgruppe von 18 bis 60 Jahren - Einzigartige zulassungsrelevante Studie in zehn Ländern und in sich ....
Leader berates North Korean officials for ‘crucial’ virus lapse As COVID recedes in prisons, will any lessons learned stick?
HERE’S WHAT ELSE IS HAPPENING: TUBINGEN, Germany German vaccine maker CureVac says younger people could benefit from its coronavirus shot, following disappointing results two weeks ago in a broader age group. The company said Wednesday that its vaccine is 53% effective against COVID-19 of any severity in 18- to 60-year-olds. Overall, though, CurveVac says the shot is 48% effective, based on 83 cases in the vaccine group and 145 in the placebo group. The World Health Organization has said vaccines with an efficacy above 50% are worth using, though many of those already approved have a far higher rate. ....